UViiVE

UViiVE is designing a new class of molecules called "dermalogiics", focused on making human's largest organ - skin - happier and healthier. Our first product is built to target the molecular trigger that begins the cascade leading to sunburn, an issue afflicting 100M Americans every year. We've known about this solution for nearly a decade, however only now with the advent of "Generative Biology" and the ability to intentionally design peptides and proteins with AI is UViiVE possible. The post-sunburn market itself is a $1B opportunity that is currently served with over the counter products focused only on symptoms. Critically, our first product will be commercialized via the Modernization of Cosmetics Reform Act (MoCRA), an accelerated path to market focused on cosmetic claims, not therapeutic claims, meaning product launch in May 2027 - a timeline unheard of for biotech.